# This super composite rating is the result of a weighted average of the rankings based on the following ratings.

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- The Trader super rating uses a four-month EPS revision window for its calculation.
- The Investor super composite rating incorporates a one-year EPS revision period, differing from the Trader metric.
- Global composite ratings require coverage by at least four out of five specified metrics for calculation.
- Quality composite ratings only require coverage by two out of three component ratings to be generated.

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/us-fda-approves-abbvie-s-rare-blood-cancer-drug-ce7f5ad3dd8efe20)

---

Canonical: https://newsio.io/n/efd61530-1eee-4481-b14f-cfa02e852c83/this-super-composite-rating-is-the-result-of-a-weighted-average-of-the-rankings
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works